HOME >> BIOLOGY >> NEWS
Enzyme mimetic reduces tissue damage in colitis animal study

Study further demonstrates selective, anti-inflammatory properties of small-molecule compounds

St. Louis, MO, December 12, 2001 The estimated 1 to 2 million Americans suffering from inflammatory bowel disease may benefit from a potential new treatment, using small-molecule enzyme mimetics, based on research published in the European Journal of Pharmacology.

The preclinical study conducted by MetaPhore Pharmaceuticals, Inc. of St. Louis, MO and the University of Messina (Italy) showed that a superoxide dismutase (SOD) enzyme mimetic significantly reduced the extent and severity of inflammation and tissue damage to the intestinal wall in an animal model of colitis. Researchers also observed a marked reduction in the diarrhea and body weight loss typical of this disease.

The SOD mimetic, M40403, was also shown to reduce elevated levels of two pro-inflammatory cytokines, tumor necrosis factor alpha (TNF-) and interleukin-1 (IL-1), implicated in the development of inflammatory bowel disease. M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to selectively remove superoxide, a free radical that, in excess, has been shown to contribute to inflammatory pathways and to regulate cytokine release.

In addition, M40403 reduced the production of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and P-selectin, in the intestinal wall of the animals. These adhesion molecules appear to play a major role in the development and persistence of inflammatory bowel disease in humans by promoting infiltration of inflammatory cells (neutrophils) into the intestine wall.

Inflammatory bowel disease includes two specific disorders: Ulcerative colitis, which affects the inner lining of the lower colon, and Crohns disease, which extends into the deeper layers of the intestinal wall. In Crohns disease, the damage to the intestine can be so great that large open
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
12-Dec-2001


Page: 1 2

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme studies at Brookhaven Lab may lead to new antiviral agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... for the life sciences industry, today announced the release of its signature ... for Medical Science Liaisons (MSLs) and other field medical professionals. , ...
(Date:7/18/2020)... DAYTON, Ohio (PRWEB) , ... July 16, 2020 ... ... clinical data solutions to aid in the early detection and prevention of high-burden ... partnership to enable US-based hospitals and healthcare organizations to utilize existing data in ...
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , a ... 2020, despite many obstacles created as a result of COVID-19. As a provider ... partnered medical practices and medical manufacturers by expanding access to device offerings, technology ...
Breaking Biology Technology:
Cached News: